Module 3: Secondary Pharmacology in Drug Discovery

Recorded On: 04/09/2026

image
image


This presentation will explore the role of secondary pharmacology in drug discovery, focusing on the identification and evaluation of off-target effects—pharmacological interactions of a compound with unintended targets. The session will highlight how secondary pharmacology assessments are integrated across all phases of drug discovery, and, when relevant, during clinical development and in regulatory submissions. The presentation will cover a range of methodological approaches, including in silico, in vitro, ex vivo, and in vivo studies used to assess the risk of off-target pharmacologic activity. The approach to off-target profiling across therapeutic modalities will be covered. Real-world case studies involving experimental compounds will be shared to illustrate practical applications and decision-making based on secondary pharmacology data.

Key:

Complete
Failed
Available
Locked
Module 3 Secondary Pharmacology in Drug Discovery
Module 3: Secondary Pharmacology in Drug Discovery, Jean-Pierre Valentin, PhD, HDR, ERT, DSP, FRCPath
Recorded 04/09/2026  |  90 minutes
Recorded 04/09/2026  |  90 minutes This presentation will explore the role of secondary pharmacology in drug discovery, focusing on the identification and evaluation of off-target effects—pharmacological interactions of a compound with unintended targets. The session will highlight how secondary pharmacology assessments are integrated across all phases of drug discovery, and, when relevant, during clinical development and in regulatory submissions. The presentation will cover a range of methodological approaches, including in silico, in vitro, ex vivo, and in vivo studies used to assess the risk of off-target pharmacologic activity. The approach to off-target profiling across therapeutic modalities will be covered. Real-world case studies involving experimental compounds will be shared to illustrate practical applications and decision-making based on secondary pharmacology data.
You must register to access.
Survey
9 Questions
9 Questions ACT values your feedback. Please help us continue to provide high-quality education offerings by completing the short survey.
You must register to access.
Certificate
No credits available  |  Certificate available
No credits available  |  Certificate available Please complete the survey to access your course certificate.
You must register to access.
Jean-Pierre Valentin, PhD, HDR, ERT, DSP, FRCPath

Jean-Pierre Valentin, PhD, HDR, ERT, DSP, FRCPath

UCB

Dr. Jean-Pierre Valentin is a scientist with more than 30 years of experience in the pharmaceutical industry in a variety of scientific and leadership roles. After earning his PhD in Physiology and Pharmacology from the University of Montpellier, France, he completed a postdoctoral fellowship at UCSF. He began his career at the Pierre Fabre Research Centre, where he contributed to the discovery and progression of three candidate drugs. 

He then joined AstraZeneca, where he established and led the Department of Safety Pharmacology, contributing to the safety evaluation of approximately 200 candidate drugs across a wide range of therapeutic areas, several of which advanced to successful registration. In 2014, he moved to UCB-Biopharma as Senior Director to lead the Investigative Toxicology unit, supporting the company’s portfolio across multiple therapeutic areas and drug modalities, currently acting as Fellow, Strategic Advisor. 

Dr. Valentin is actively engaged in the scientific community. He is a former President of the Safety Pharmacology Society; current co-chair of the HESI Proarrhythmia Subcommittee and Cardiac Steering Team; and serves on the HESI Board of Trustees and Executive Committee. He also chairs the IQ-DruSafe Secondary Pharmacology Working Group and represents EFPIA on the ICH E14/S7B committee. 

He has been involved extensively in training, education, and mentoring through scientific societies, universities, and trade associations. He is the author or co-author of several patents and more than 250 peer-reviewed publications and book chapters.